Latest Breaking News On - Narrow therapeutic - Page 1 : comparemela.com

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as.

Paul nitschmannAdvisory committeeRegulatory affairs at interceptDrug administrationGlobenewswire incInternational normalized ratioIntercept pharmaceuticals incNew drug applicationPrescription drug user fee actSenior vice presidentRegulatory affairsNarrow therapeuticBile salt effluxFull prescribing informationIntercept pharmaceuticals

Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023

Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRadhika nairM michelle berreyDarren wheelerRobertg gishAlan bonderElizabeths malechaResearch developmentInternational normalized ratioIntercept pharmaceuticals incCompany on linkedinChief medical officerLoma linda university departmentObeticholic acidPrognostic thresholdsGamma glutamyl transferase

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Inte.

United statesComunidad autonoma de catalunaTrezzano rosaFrancesco balestrieriJemma hodgesGea gardiniLuca bolzoniStefano golinelliSimona gelpiEmma valgimigliAlberto colombiniCorporation law of the state delawareIntercept pharmaceuticals incInternational normalized ratioInterstellar acquisition incDrug administration

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 Alfasigma S.p.A. and Intercept Pharmaceuticals, Inc. announced today the completion of the acquisition of Intercept by Alfasigma through its.

United statesTrezzano rosaComunidad autonoma de catalunaAlberto colombiniStefano golinelliSimona gelpiEmma valgimigliGea gardiniFrancesco balestrieriJemma hodgesLuca bolzoniIntercept pharmaceuticals incGlobenewswire incCorporation lawDrug administrationInterstellar acquisition inc

Intercept Pharmaceuticals, Inc : Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

Intercept Pharmaceuticals, Inc : Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNareg sagherianAdvanz pharmaJerry dursoKaren prebleExchange commissionGlobal corporate communicationsInternational normalized ratioIntercept pharmaceuticals incCompany on twitterSecurities exchangeDrug administrationChief executive officerSecond quarterAccepted accounting principlesOperating expenses